Long-term safety of ustekinumab in patients with moderate to severe psoriasis through up to 5 years of continuous follow-up

被引：0
|
作者：
Papp, Kim [1 ]
Reich, Kristian [2 ]
Lebwohl, Mark [3 ]
Szapary, Philippe [4 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] Mt Sinai Sch Med, New York, NY USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2013年 / 68卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB205 / AB205
页数：1
相关论文
共 50 条
  • [1] Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
    Papp, K. A.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. -C.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (04) : 844 - 854
  • [2] Long-term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P. O.
    Gordon, K. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 : 63 - 64
  • [3] Long term efficacy and safety of ustekinumab in patients with moderate to severe psoriasis through 5 years of follow-up: results from the PHOENIX 1 long-term extension
    Papp, K.
    Kimball, A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K.
    JOURNAL OF DERMATOLOGY, 2012, 39 : 239 - 240
  • [4] Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
    Langley, R. G.
    Lebwohl, M.
    Krueger, G. G.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. C.
    You, Y.
    Poulin, Y.
    Korman, N.
    Prinz, J. C.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1371 - 1383
  • [5] Long-Term Safety Of Ustekinumab: 5 Years Of Follow-Up From The Psoriasis Clinical Development Program Including Patients With Psoriatic Arthritis
    Papp, Kim
    Griffiths, Christopher E. M.
    Gordon, Kenneth B.
    Lebwohl, Mark
    Szapary, Philippe O.
    Wasfi, Yasmine
    Chan, Daphne
    Shen, Yaung-Kaung
    Ho, Vincent
    Ghislain, Pierre-Dominique
    Strober, Bruce
    Reich, Kristian
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S139 - S140
  • [6] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, K.
    Griffiths, C. E. M.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    SWISS MEDICAL WEEKLY, 2014, 144 : 5S - 5S
  • [7] Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis
    Papp, Kim
    Reich, Kristian
    Lebwohl, Mark
    Wasfi, Yasmine
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB174 - AB174
  • [8] LONG-TERM SAFETY OF USTEKINUMAB: 5 YEARS OF FOLLOW-UP FROM THE PSORIASIS CLINICAL DEVELOPMENT PROGRAM INCLUDING PATIENTS WITH PSORIATIC ARTHRITIS
    Papp, K.
    Griffiths, C.
    Gordon, K.
    Lebwohl, M.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Shen, Y. K.
    Ho, V.
    Ghislain, P. D.
    Strober, B.
    Reich, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 680 - 680
  • [9] Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
    Kimball, A. B.
    Papp, K. A.
    Wasfi, Y.
    Chan, D.
    Bissonnette, R.
    Sofen, H.
    Yeilding, N.
    Li, S.
    Szapary, P.
    Gordon, K. B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) : 1535 - 1545
  • [10] An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
    Reich, Kristian
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Szapary, Philippe O.
    Yeilding, Newman
    Wasfi, Yasmine
    Ott, Elyssa
    Hsu, Ming-Chun
    Lebwohl, Mark
    Gordon, Kenneth B.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (03) : 300 - 312
12345